Jazz Pharmaceuticals Plc Stock Rating Lowered by Zacks (JAZZ)
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday, AnalystRatings.NET reports. They currently have a $95.00 price objective on the stock. Zacks‘ target price suggests a potential upside of 13.39% from the stock’s previous close.
Several other analysts have also recently commented on the stock. Analysts at Guggenheim raised their price target on shares of Jazz Pharmaceuticals Plc from $90.00 to $105.00 in a research note to investors on Thursday, September 19th. They now have a “buy” rating on the stock. Separately, analysts at Cowen and Company raised their price target on shares of Jazz Pharmaceuticals Plc from $85.00 to $120.00 in a research note to investors on Thursday, September 19th. They now have an “outperform” rating on the stock. Finally, analysts at Goldman Sachs Group Inc. initiated coverage on shares of Jazz Pharmaceuticals Plc in a research note to investors on Tuesday, September 17th. They set a “buy” rating on the stock. One analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Jazz Pharmaceuticals Plc presently has a consensus rating of “Buy” and an average target price of $88.88.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) traded down 5.83% during mid-day trading on Tuesday, hitting $83.78. The stock had a trading volume of 2,236,558 shares. Jazz Pharmaceuticals Plc has a one year low of $47.37 and a one year high of $93.84. The stock has a 50-day moving average of $87.57 and a 200-day moving average of $71.06. The company has a market cap of $4.872 billion and a P/E ratio of 17.06.
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by $0.09. The company had revenue of $208.30 million for the quarter, compared to the consensus estimate of $208.71 million. During the same quarter in the previous year, the company posted $1.09 earnings per share. The company’s revenue for the quarter was up 67.7% on a year-over-year basis.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.